Ash 2022 – the sickle cell race hots up
Sangamo emulates Editas, while Crispr/Vertex and Bluebird add weight to their ambitions.
When is big pharma no longer big pharma?
After a bruising few months for GSK, 17 global drug makers now have a higher market cap than the UK company.
Ash 2022 preview – waiting for Editas
Data on the group’s sickle cell project do not feature in the regular abstracts, while Bluebird walks away from its short hairpin contender.
Few safe havens surface in another down quarter for biopharma
Lilly, Daiichi and Vertex are on track to be 2022’s best performing stocks, as the Covid crash continues.
